{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T15:59:03Z","timestamp":1781193543654,"version":"3.54.1"},"reference-count":40,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,3]],"date-time":"2026-05-03T00:00:00Z","timestamp":1777766400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.clinthera.2026.04.021","type":"journal-article","created":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T11:18:47Z","timestamp":1779103127000},"page":"648-655","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Study Design Considerations for the Evaluation of Pancreatic Enzyme Replacement Therapy (PERT) Products in People with Cystic Fibrosis: An Update"],"prefix":"10.1016","volume":"48","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0557-7277","authenticated-orcid":false,"given":"Michael W.","family":"Konstan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitchell L.","family":"Ramsey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meghana","family":"Sathe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. Jay","family":"Freeman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven D.","family":"Freedman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah J.","family":"Schwarzenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colin","family":"O\u2019Rourke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frankline M.","family":"Onchiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Setiawan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph M.","family":"Pilewski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Mayer-Hamblett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2026.04.021_bib0001","doi-asserted-by":"crossref","first-page":"731","DOI":"10.4155\/cli.13.63","article-title":"Study design considerations for evaluating the efficacy and safety of pancreatic enzyme replacement therapy in patients with cystic fibrosis","volume":"3","author":"Konstan","year":"2013","journal-title":"Clin Investig (L)"},{"issue":"72","key":"10.1016\/j.clinthera.2026.04.021_bib0002","first-page":"19524","article-title":"Guidance for industry on exocrine pancreatic insufficiency drug products\u2014submitting new drug applications; availability","volume":"71","year":"2006","journal-title":"Fed Regist"},{"issue":"44","key":"10.1016\/j.clinthera.2026.04.021_bib0003","first-page":"12932","article-title":"Guidance for industry: exocrine pancreatic insufficiency drug products\u2014submitting new drug applications; withdrawal of guidance","volume":"85","year":"2020","journal-title":"Fed Regist"},{"key":"10.1016\/j.clinthera.2026.04.021_bib0004","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.jcf.2009.08.008","article-title":"Efficacy and safety of Creon 24,000 in subjects with exocrine pancreatic insufficiency due to cystic fibrosis","volume":"8","author":"Trapnell","year":"2009","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.clinthera.2026.04.021_bib0005","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.jcf.2009.07.006","article-title":"EUR-1008 pancreatic enzyme replacement is safe and effective in patients with cystic fibrosis and pancreatic insufficiency","volume":"8","author":"Wooldridge","year":"2009","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.clinthera.2026.04.021_bib0006","doi-asserted-by":"crossref","DOI":"10.1155\/2010\/898193","article-title":"Efficacy and safety of a new formulation of pancrelipase (Ultrase MT20) in the treatment of malabsorption in exocrine pancreatic insufficiency in cystic fibrosis","author":"Konstan","year":"2010","journal-title":"Gastroenterol Res Pr"},{"key":"10.1016\/j.clinthera.2026.04.021_bib0007","doi-asserted-by":"crossref","first-page":"723","DOI":"10.4155\/cli.13.62","article-title":"Efficacy and safety of a unique enteric-coated bicarbonate-buffered pancreatic enzyme replacement therapy in children and adults with cystic fibrosis","volume":"3","author":"Konstan","year":"2013","journal-title":"Clin Investig (L)"},{"key":"10.1016\/j.clinthera.2026.04.021_bib0008","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.jcf.2011.04.005","article-title":"Efficacy and safety of PANCREAZE(R) for treatment of exocrine pancreatic insufficiency due to cystic fibrosis","volume":"10","author":"Trapnell","year":"2011","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.clinthera.2026.04.021_bib0009","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.jcf.2011.07.001","article-title":"Liprotamase 726 Study Group, International phase III trial of liprotamase efficacy and safety in pancreatic-insufficient cystic fibrosis patients","volume":"10","author":"Borowitz","year":"2011","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.clinthera.2026.04.021_bib0010","doi-asserted-by":"crossref","first-page":"147","DOI":"10.4172\/Clinical-Investigation.1000141","article-title":"A comparison of liprotamase, a non-porcine pancreatic enzyme replacement therapy, to porcine extracted pancrelipase in a noninferiority randomized clinical trial in patients with cystic fibrosis","volume":"8","author":"Konstan","year":"2018","journal-title":"Clin Investig"},{"key":"10.1016\/j.clinthera.2026.04.021_bib0011","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.jpeds.2016.05.049","article-title":"Safety and efficacy of a novel microbial lipase in patients with exocrine pancreatic insufficiency due to cystic fibrosis: a randomized controlled clinical trial","volume":"176","author":"Heubi","year":"2016","journal-title":"J Pediatr"},{"key":"10.1016\/j.clinthera.2026.04.021_bib0012","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1186\/1745-6215-12-106","article-title":"Through the looking glass: understanding non-inferiority","volume":"12","author":"Schumi","year":"2011","journal-title":"Trials"},{"key":"10.1016\/j.clinthera.2026.04.021_bib0013","unstructured":"Food and Drug Administration, HHS. Non-inferiority clinical trials to establish effectiveness guidance for industry, 2016. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/non-inferiority-clinical-trials. (Accessed April 21, 2025)."},{"key":"10.1016\/j.clinthera.2026.04.021_bib0014","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1002\/sim.2855","article-title":"Current issues in non-inferiority trials","volume":"27","author":"Fleming","year":"2008","journal-title":"Stat Med"},{"key":"10.1016\/j.clinthera.2026.04.021_bib0015","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1111\/j.1651-2227.2004.tb02715.x","article-title":"Faecal elastase-1 test is superior to faecal lipase test in the assessment of exocrine pancreatic function in cystic fibrosis","volume":"93","author":"Walkowiak","year":"2004","journal-title":"Acta Paediatr"},{"key":"10.1016\/j.clinthera.2026.04.021_bib0016","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.jpeds.2004.04.049","article-title":"Use of fecal elastase-1 to classify pancreatic status in patients with cystic fibrosis","volume":"145","author":"Borowitz","year":"2004","journal-title":"J Pediatr"},{"key":"10.1016\/j.clinthera.2026.04.021_bib0017","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.pan.2021.11.005","article-title":"Staging exocrine pancreatic dysfunction","volume":"22","author":"Khan","year":"2022","journal-title":"Pancreatology"},{"key":"10.1016\/j.clinthera.2026.04.021_bib0018","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1016\/j.cgh.2018.01.027","article-title":"Diagnostic performance of measurement of fecal elastase-1 in detection of exocrine pancreatic insufficiency: systematic review and meta-analysis","volume":"16","author":"Vanga","year":"2018","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.clinthera.2026.04.021_bib0019","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.jcf.2016.02.010","article-title":"Comparison of two pancreatic enzyme products for exocrine insufficiency in patients with cystic fibrosis","volume":"15","author":"Taylor","year":"2016","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.clinthera.2026.04.021_bib0020","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.clinthera.2010.01.012","volume":"32","author":"Graff","year":"2010","journal-title":"Clin Ther"},{"key":"10.1016\/j.clinthera.2026.04.021_bib0021","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1097\/MPG.0b013e31820e208e","article-title":"Treatment of infants and toddlers with cystic fibrosis-related pancreatic insufficiency and fat malabsorption with pancrelipase MT","volume":"53","author":"Van de Vijver","year":"2011","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.clinthera.2026.04.021_bib0022","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1097\/MPA.0b013e3181a85eaf","article-title":"Efficacy and tolerability of Creon for Children in infants and toddlers with pancreatic exocrine insufficiency caused by cystic fibrosis: an open-label, single-arm, multicenter study","volume":"38","author":"Colombo","year":"2009","journal-title":"Pancreas"},{"key":"10.1016\/j.clinthera.2026.04.021_bib0023","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1111\/j.1365-2036.2004.02261.x","article-title":"Ultrase MT12 and ultrase MT20 in the treatment of exocrine pancreatic insufficiency in cystic fibrosis: safety and efficacy","volume":"20","author":"Konstan","year":"2004","journal-title":"Aliment Pharmacol Ther"},{"issue":"3","key":"10.1016\/j.clinthera.2026.04.021_bib0024","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1007\/s10620-024-08728-8","article-title":"Proton-pump inhibitors and fat absorption in cystic fibrosis and pancreatic insufficiency: a randomized crossover pilot trial","volume":"70","author":"Phillips","year":"2025","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.clinthera.2026.04.021_bib0025","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.jcf.2022.08.008","article-title":"Cystic fibrosis transmembrane conductance regulator modulators and the exocrine pancreas: a scoping review","volume":"22","author":"Ramsey","year":"2023","journal-title":"J Cyst Fibros"},{"issue":"6","key":"10.1016\/j.clinthera.2026.04.021_bib0026","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/j.jcf.2025.09.004","article-title":"Real-world pancreatic function recovery and fluctuation in young children with cystic fibrosis on elexacaftor\/tezacaftor\/ivacaftor","volume":"24","author":"Schembri","year":"2025","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.clinthera.2026.04.021_bib0027","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.jcf.2022.10.003","article-title":"Promise Study Group, Elexacaftor\/tezacaftor\/ivacaftor and gastrointestinal outcomes in cystic fibrosis: report of promise-GI","volume":"22","author":"Schwarzenberg","year":"2023","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.clinthera.2026.04.021_bib0028","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.jcf.2008.07.003","article-title":"Pancreatic enzyme replacement therapy for young cystic fibrosis patients","volume":"8","author":"Munck","year":"2009","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.clinthera.2026.04.021_bib0029","article-title":"Pancreatic enzyme replacement therapy for people with cystic fibrosis","volume":"8","author":"Somaraju","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.clinthera.2026.04.021_bib0030","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000541326","article-title":"Clinical efficacy and safety of treatments for exocrine pancreatic insufficiency: a systematic literature review","author":"Chu","year":"2024","journal-title":"Digestion"},{"key":"10.1016\/j.clinthera.2026.04.021_bib0031","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1007\/s11136-004-9567-x","article-title":"Development and psychometric evaluation of the patient assessment of upper gastrointestinal symptom severity index (PAGI-SYM) in patients with upper gastrointestinal disorders","volume":"13","author":"Rentz","year":"2004","journal-title":"Qual Life Res"},{"key":"10.1016\/j.clinthera.2026.04.021_bib0032","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1111\/apt.14349","article-title":"The PAC-SYM questionnaire for chronic constipation: defining the minimal important difference","volume":"46","author":"Yiannakou","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.clinthera.2026.04.021_bib0033","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1080\/00365520510012208","article-title":"Development and validation of the patient assessment of constipation quality of life questionnaire","volume":"40","author":"Marquis","year":"2005","journal-title":"Scand J Gastroenterol"},{"issue":"6","key":"10.1016\/j.clinthera.2026.04.021_bib0034","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.3390\/jcm13061650","article-title":"Scoring abdominal symptoms in people with cystic fibrosis","volume":"13","author":"Tabori","year":"2024","journal-title":"J Clin Med"},{"key":"10.1016\/j.clinthera.2026.04.021_bib0035","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/j.jcf.2020.12.021","article-title":"Designing the GALAXY study: partnering with the cystic fibrosis community to optimize assessment of gastrointestinal symptoms","volume":"20","author":"Freeman","year":"2021","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.clinthera.2026.04.021_bib0036","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1016\/j.jcf.2024.07.013","article-title":"Estimating minimal clinically important difference (MCID) for gastrointestinal symptoms in cystic fibrosis","volume":"23","author":"Lee","year":"2024","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.clinthera.2026.04.021_bib0037","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1007\/s40271-017-0233-0","article-title":"Qualitative assessment of the symptoms and impact of pancreatic exocrine insufficiency (PEI) to inform the development of a patient-reported outcome (PRO) instrument","volume":"10","author":"Johnson","year":"2017","journal-title":"Patient"},{"key":"10.1016\/j.clinthera.2026.04.021_bib0038","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.pan.2018.11.013","article-title":"Psychometric evaluation of a patient-reported outcome measure in pancreatic exocrine insufficiency (PEI)","volume":"19","author":"Johnson","year":"2019","journal-title":"Pancreatology"},{"key":"10.1016\/j.clinthera.2026.04.021_bib0039","unstructured":"Abbott. Pancreatic exocrine insufficiency questionnaire https:\/\/acare.abbott.com\/en\/digestive-health\/pei-q\/. (Accessed March 24, 2025)."},{"key":"10.1016\/j.clinthera.2026.04.021_bib0040","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1056\/NEJM197607292950503","article-title":"Hyperuricosuria due to high-dose pancreatic extract therapy in cystic fibrosis","volume":"295","author":"Stapleton","year":"1976","journal-title":"N Engl J Med"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291826001396?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291826001396?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T15:17:58Z","timestamp":1781191078000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291826001396"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":40,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S0149291826001396"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2026.04.021","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Study Design Considerations for the Evaluation of Pancreatic Enzyme Replacement Therapy (PERT) Products in People with Cystic Fibrosis: An Update","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2026.04.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}